GFAP and Alzheimer disease: Such a difference was also observed by immunohistostaining (Figure 6D,E), where untreated 3xTg-AD mice exhibited strong GFAP labeling (U-value = 3; p = 0.0556; r = 0.76) that was decreased after treatment (U-value = 2; p = 0.0317; r = 0.84).